India : MYLAN INC launches COMPREHENSIVE PORTFOLIO of 18 ANTIRETROVIRAL (ARV) PRODUCTS [TendersInfo (India)]

Mylan Inc., one of the world s leading generic and specialty pharmaceutical companies announced that it has started commercial operations in India by launching a comprehensive portfolio of 18 antiretroviral (ARV) products for the treatment of HIV/AIDS.

Mylan s mission is to provide the world s 7 billion people with access to high quality medicine. Through the initial launch in India of a broad and innovative ARV portfolio, we are taking another significant stride towards meeting that goal. We believe that Mylan can set a new standard in the treatment of HIV/AIDS in India by providing healthcare providers and those living with the disease access to high quality, affordable medicines and by supporting physicians in their efforts to educate and treat their patients through our innovation, reliability and service excellence. We see significant growth potential in India, the world s second largest pharmaceutical market by volume, and look forward to continuing to expand our operations in India in additional therapeutic categories, added Heather Bresch, CEO.

Mylan has provided reliable supplies of ARV active pharmaceutical ingredients (API) to generic drug makers.

Mylan has helped to significantly drive down the cost of ARV therapies, while ensuring that quality remains paramount. Globally, we now offer a portfolio of 43 innovative, high quality ARV drugs, and the launch of 18 of these products in India represents an exciting first step in this important market. Since Mylan s founding more than 50 years ago, we have been committed to filling unmet needs with our quality products, and we intend to maintain these same high standards with the products we sell in India, added Mylan President Rajiv Malik.

A growing portfolio of more than 1,100 generic pharmaceuticals is offered by Mylan and several brand medications.